Consensus Statement on Drug-Coated Balloons in Coronary Artery Disease from the Cardiovascular Intervention Association of Thailand
Authors:
- Pannipa SuwannasomPSPannipa Suwannasom
- Korakoth TowashirapornKTKorakoth Towashiraporn
- Worawut RoongsangmanoonWRWorawut Roongsangmanoon
- Wiwat KanjanarutjawiwatWKWiwat Kanjanarutjawiwat
- Purich SurunchupakornPSPurich Surunchupakorn
- Muenpetch MuenkaewMMMuenpetch Muenkaew
- Ply ChichareonPCPly Chichareon
- Pisit HutayanonPHPisit Hutayanon
- Anek KanoksilpAKAnek Kanoksilp
- Mann ChandavimolMCMann Chandavimol
Open Access
- 23 October 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7505
Abstract
Background: Drug-coated balloons (DCBs) have transformed percutaneous coronary intervention (PCI) by delivering antiproliferative drugs without leaving a permanent scaffold. DCB is initially indicated for in-stent restenosis (ISR) and now has expanded indication for treating small vessel disease and bifurcation lesions. However, there is a heterogeneity in the patient and lesion selection, lesion preparation techniques, and the optimal duration of dual antiplatelet therapy after DCB angioplasty. The Cardiovascular Intervention Association of Thailand (CIAT) developed a consensus statement on DCB use in coronary interventions. Methods: The CIAT expert panel systematically reviewed randomized controlled trials, meta-analyses, and real-world studies evaluating DCB therapy. Procedural strategies, imaging guidance, physiologic assessment, and antiplatelet therapy protocols were appraised. The recommendations were developed and put to an online vote. Consensus was defined when the recommendation reached 80% of votes in support of “agree” or “neutral”. Results: Clinical evidence demonstrates that DCBs achieve comparable outcomes to drug-eluting stents (DESs) in selected lesions while enabling shorter durations of dual antiplatelet therapy (DAPT), particularly beneficial for high-bleeding-risk patients. Optimal outcomes require meticulous lesion preparation, appropriate balloon sizing, and controlled vessel dissection. Intravascular imaging and physiologic assessment further refine procedural precision, while hybrid strategies combining DCBs and DESs address complex lesions and multivessel disease. The final document presents 15 consensus statements addressing indications, procedural techniques, imaging and physiologic guidance, and antiplatelet therapy recommendations. Conclusions: DCB angioplasty can be an alternative or complement to therapeutic options to DESs across multiple clinical and anatomical scenarios. The CIAT consensus provided structured recommendations to support DCB therapy in contemporary practice.Keywords
Funding Information
- Cardiovascular Intervention Association of Thailand
This publication has 154 references indexed in Scilit:
- Drug-Coated Balloons for the Treatment of Coronary Artery DiseaseJAMA Cardiology, 2025
- Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent RestenosisJAMA, 2024
- Drug‐coated balloon strategy following orbital atherectomy for calcified coronary artery compared with drug‐eluting stent: One‐year outcomes and optical coherence tomography assessmentCatheterization and Cardiovascular Interventions, 2023
- Intraplaque wiring enables drug‐coated balloons to be utilized for percutaneous recanalization of chronically occluded coronary arteriesCatheterization and Cardiovascular Interventions, 2023
- Percutaneous coronary intervention with drug‐coated balloon‐only strategy combined with single antiplatelet treatment in patients at high bleeding risk: Single center experience of a novel conceptCatheterization and Cardiovascular Interventions, 2023
- Optical coherence tomography analysis of late lumen enlargement after paclitaxel‐coated balloon angioplasty for de‐novo coronary artery diseaseCatheterization and Cardiovascular Interventions, 2020
- Efficacy of drug‐coated balloon angioplasty after directional coronary atherectomy for coronary bifurcation lesions (DCA/DCB registry)Catheterization and Cardiovascular Interventions, 2020
- Percutaneous coronary intervention with drug‐coated balloon‐only strategy in stable coronary artery disease and in acute coronary syndromes: An all‐comers registry studyCatheterization and Cardiovascular Interventions, 2018
- Prospective, large‐scale multicenter trial for the use of drug‐coated balloons in coronary lesions: The DCB‐only All‐Comers RegistryCatheterization and Cardiovascular Interventions, 2018
- Long‐term efficacy of drug coated balloons compared with new generation drug‐eluting stents for the treatment of de novo coronary artery lesionsCatheterization and Cardiovascular Interventions, 2018